IceCure Medical Ltd. (NASDAQ:ICCM – Get Free Report) has earned an average recommendation of “Hold” from the five ratings firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $62.70.
A number of equities analysts have weighed in on ICCM shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of IceCure Medical in a research report on Tuesday, April 21st. Alliance Global Partners started coverage on shares of IceCure Medical in a research note on Monday, May 4th. They set a “buy” rating on the stock. Maxim Group cut their price objective on shares of IceCure Medical from $90.00 to $30.00 and set a “buy” rating for the company in a report on Thursday, May 14th. Finally, Wall Street Zen upgraded shares of IceCure Medical to a “sell” rating in a research note on Sunday, July 12th.
View Our Latest Research Report on IceCure Medical
Hedge Funds Weigh In On IceCure Medical
IceCure Medical Stock Performance
ICCM stock opened at $3.65 on Friday. The stock has a fifty day moving average of $5.26 and a 200-day moving average of $12.11. IceCure Medical has a fifty-two week low of $2.12 and a fifty-two week high of $42.00. The company has a market capitalization of $12.52 million, a price-to-earnings ratio of -0.51 and a beta of 0.43.
IceCure Medical (NASDAQ:ICCM – Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.03). The firm had revenue of $0.91 million during the quarter, compared to the consensus estimate of $1.34 million. IceCure Medical had a negative net margin of 441.60% and a negative return on equity of 211.73%. Equities analysts predict that IceCure Medical will post -3.51 EPS for the current year.
IceCure Medical Company Profile
IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.
Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.
Read More
- Five stocks we like better than IceCure Medical
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
- Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth
- TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident
- GE Aerospace Faces a Prove-It Moment in Q2 Earnings
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.
